Jamil Muradov is addressing the significant issue of concussions affecting over 42 million individuals annually, leading to long-term complications in some cases. His proposed solution involves using the clinically approved drug Memantine to inhibit abnormal brain activity triggered by concussions, showing promise in pre-clinical trials for potential use in human clinical trials and preventive sports concussion treatment.
Falling Walls
Falling Walls Science Summit 2023
Login or Register
You need to be logged in to use this feature.
Breaking the Wall of Concussion Complications
Jamil Muradov is a PhD candidate in Dr Friedman’s lab with an undergraduate degree in life science with distinction and a Master’s degree in biomedical science from Queen’s University. He is focusing on understanding early neurovascular events that occur following traumatic brain injury. His goal is to identify pathological brain activity patterns that may underlie long-term brain injury. Jamil wants to continue investigating fundamental processes in the brain that underlie a variety of pathophysiological conditions. He hopes his research will inform novel therapeutic strategies that would make treatment methodologies more accessible globally.
Further Activities to have a look at